Chemours in $455M North Carolina PFAS settlement
Rhea-AI Filing Summary
Chemours Co (CC) entered into a Settlement Agreement with the State of North Carolina and 11 local entities to resolve claims relating to PFAS and other emissions from its Fayetteville Works facility, as well as certain PFAS contamination elsewhere in the state, including from aqueous film-forming foam. The agreement calls for aggregate payments of $455 million over 15 years, beginning within 30 days of execution, and remains subject to court orders dismissing the covered claims. Under existing cost-sharing arrangements, Chemours will bear 50% of the settlement payments, with DuPont and Corteva sharing the remaining 50%. Chemours states its approximately $180 million net present value share is covered by existing accruals, and expects about $50 million of payments in the next twelve months. The Settlement Amount will count as about $210 million of qualified spend under the parties’ $4 billion MOU cap, and combined with a 2025 New Jersey settlement eliminates the need for further contributions to the MOU escrow account, including Chemours’ $50 million contribution previously due in September 2026.
Positive
- $455 million multi-party settlement substantially resolves significant PFAS-related claims in North Carolina, providing greater clarity around related legacy liabilities for Chemours.
- Chemours’ ~$180 million net present value share of settlement payments is stated as covered by existing accruals, limiting incremental impact on current reported liabilities.
- Combined North Carolina and 2025 New Jersey settlements mean no further contributions are required to the MOU escrow, including Chemours’ $50 million payment previously due in September 2026.
Negative
- The agreement entails $455 million in total cash payments over 15 years, with Chemours responsible for 50%, creating ongoing settlement-related cash outflows.
- Settlement effectiveness is subject to court dismissals of covered litigations, so final resolution of these PFAS-related matters is not yet fully completed.
Filing Explained
The settlement includes
8-K Event Classification
Key Figures
Key Terms
PFAS technical
Memorandum of Understanding regulatory
net present value financial
Consent Order regulatory
aqueous film forming foam technical
qualified spend financial
FAQ
How much of the $455 million North Carolina settlement will Chemours (CC) ultimately bear?
Over what period will the North Carolina settlement payments be made by Chemours (CC) and partners?
How does the settlement affect Chemours’ (CC) PFAS cost-sharing MOU with DuPont and Corteva?
What portion of the settlement relates to PFAS contamination outside the Fayetteville Works site?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported)
(Exact Name of Registrant as Specified in Its Charter)
|
|
|||
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
Of Incorporation) |
|
File Number) |
|
Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
|
☐ |
|
Item 1.01 Entry into a Material Definitive Agreement.
On September 9, 2026, The Chemours Company (“Chemours”), DuPont de Nemours, Inc. (“DuPont”), Corteva, Inc. and EIDP, Inc., a subsidiary of Corteva, Inc. (together with Corteva, Inc., “Corteva”), entered into a settlement agreement (the “Settlement Agreement”) with the State of North Carolina and 11 local entities located in the vicinity of Chemours’ Fayetteville Works facility, including Bladen County, Brunswick County, Columbus County, Cumberland County, New Hanover County, Robeson County, Sampson County, Town of Wrightsville Beach, City of Lumberton, Village of Bald Head Island and the Lower Cape Fear Water and Sewer Authority (collectively, the “Local Entities,” and together with the State of North Carolina, the “Claimants”).
The Settlement Agreement resolves all claims asserted by the Claimants relating to PFAS and other emissions from the Fayetteville Works facility, as well as claims asserted by the State of North Carolina relating to PFAS contamination unrelated to such facility, including contamination associated with the use of aqueous film-forming foam. In addition, the Settlement Agreement acknowledges that certain obligations under the 2019 Consent Order with the State of North Carolina have been completed and establishes procedures to resolve certain remaining obligations relating to off-site areas, including implementation of drinking water programs.
The Settlement Agreement includes an aggregate payment to the Claimants in the amount of $455 million (the “Settlement Amount”), payable over a 15-year period beginning within 30 days of the execution date of the Settlement Agreement.
The Settlement Agreement remains subject to the entry of orders dismissing the claims covered therein. The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Settlement Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Consistent with the January 2021 Memorandum of Understanding (“MOU”) between the Chemours, DuPont, and Corteva, Chemours will be responsible for 50% of settlement payments, and DuPont and Corteva will be responsible for the remaining 50%. In addition, Chemours, DuPont, and Corteva have mutually worked together to reach certain understandings concerning the MOU, including the valuation of the Settlement Amount and potential future multi-year settlements on a net present value basis for purposes of calculating qualified spend, as they continue to work together to address legacy PFAS-related litigation matters. Pursuant to these understandings, for purposes of calculating the amount of qualified spend applied against the MOU’s $4 billion aggregate qualified spend cap, the Settlement Amount will be applied against such cap in the amount of $210 million, reflecting the net present value spread equally over a twenty-five-year period from the date the Settlement becomes final (rather than the actual timing of the payments) and using an 8% discount rate. The companies have agreed to use this net present value methodology for potential future settlements with multi-year payments.
In addition, since the aggregate payments to be made in connection with the Settlement Agreement and the companies’ 2025 settlement with the State of New Jersey will qualify for withdrawal from the companies’ MOU escrow account and exceed the companies’ future escrow contribution obligations, all future contributions to the MOU escrow account will be considered satisfied by the companies’ New Jersey and North Carolina settlement payments, including Chemours’ $50 million escrow contribution that would have been due in September 2026.
Item 7.01 Regulation FD Disclosure.
On September 10, 2026, Chemours issued a press release announcing the matters described in this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about expected performance and impact of the cost-sharing arrangements by and among Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Factors that could cause or contribute to these differences include, but are not limited to: the outcome of the final court approval process for the Consent Decree, including any appeals; the outcome of any pending or future litigation related to PFAS or PFOA, including personal injury claims and natural resource damages claims; the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of injunctive actions and mitigation projects under the Consent Order; changes in laws and regulations applicable to PFAS chemicals; the performance by each of the parties of their respective obligations under the cost-sharing arrangement. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Further lists and descriptions of risks and uncertainties can be found in Chemours’ annual report on Form 10-K for the year ended December 31, 2025 and subsequent reports on Form 10-Q and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Consequences of material differences in results as compared
with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Chemours’ consolidated financial condition, results of operations, credit rating or liquidity. Chemours does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
10.1 Settlement Agreement, dated September 9, 2026, by and among The Chemours Company, DuPont de Nemours, Inc., Corteva, Inc., EIDP, Inc. and certain other parties set forth therein.
99.1 Press Release, dated September 10, 2026.
104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY |
||
|
||
By: |
|
/s/ Shane Hostetter |
|
|
Shane Hostetter |
|
|
Senior Vice President, Chief Financial Officer |
Date: |
|
September 10, 2026 |
EXHIBIT 99.1
Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
Wilmington, Del., September 10, 2026 – The Chemours Company (NYSE: CC) (the “Company”) today announced that, along with DuPont de Nemours, Inc. (“Dupont”) and Corteva, Inc. (“Corteva”), it has entered into a settlement (the “Settlement”) with the State of North Carolina (the “State”) and 11 local entities* in the vicinity of the Company’s Fayetteville Works facility that were excluded from the U.S. Public Water System Class Settlement approved in 2024.
The Settlement resolves litigations brought by the State and the settling local entities relating to PFAS and other historical discharges from Fayetteville Works, as well as the State’s claims of PFAS contamination unrelated to that site, including from the use of AFFF.
The settlement also acknowledges the substantial progress made under the Company’s 2019 Consent Order with the State (the “Consent Order”). Since 2019, Chemours has made substantial investments to significantly reduce PFAS emissions from Fayetteville Works and mitigate off-site impacts in the surrounding communities. The agreement recognizes that several Consent Order provisions have been completed and establishes procedures to address certain remaining obligations relating to off-site areas, including implementation of drinking water programs.
Settlement payments will total $455 million (the “Settlement Amount”) over a 15-year period beginning within 30 days of the execution date of the agreement. Chemours’ share of expected payments over the next twelve months is approximately $50 million. Of the total settlement amount, $18 million is attributed to alleged PFAS contamination unrelated to Fayetteville Works.
The terms of the Settlement, including a further description of claims released and not released, are set forth in the Settlement Agreement, which remains subject to entry of dismissals of the covered litigations.
EXHIBIT 99.1
Consistent with the January 2021 Memorandum of Understanding (“MOU”) between the Company, DuPont, and Corteva, Chemours will be responsible for 50% of settlement payments, and DuPont and Corteva will be responsible for the remaining 50%. In addition, Chemours, DuPont, and Corteva have mutually worked together to reach certain understandings concerning the MOU, including the valuation of the Settlement and potential future multi-year settlements on a net present value basis for purposes of calculating qualified spend, as they continue to work together to address legacy PFAS-related litigation matters. Pursuant to these understandings, for purposes of calculating the amount of qualified spend , the Settlement Amount will account for approximately $210 million.
In addition, all future contributions to the MOU escrow account will be considered satisfied , including Chemours’ $50 million escrow contribution that would have been due in September 2026.
This settlement marks further progress under the Strengthening the Long-Term Pillar of Chemours' Pathway to Thrive strategy and ongoing efforts to address legacy liabilities and community concerns. The agreement provides greater clarity regarding the liabilities associated with these matters, acknowledges the significant progress already made at Fayetteville Works, and supports the Company's continued operation of this important manufacturing facility.
* The 11 local entities are Bladen County, Brunswick County, Columbus County, Cumberland County, New Hanover County, Robeson County, Sampson County, Town of Wrightsville Beach, City of Lumberton, Village of Bald Head Island, and Lower Cape Fear Water and Sewer Authority.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,”
EXHIBIT 99.1
“estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about expected performance and impact of the cost-sharing arrangements by and between Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Factors that could cause or contribute to these differences include, but are not limited to: the relevant courts’ entry of dismissals required for the Settlement Agreement to become final; the outcome of any pending or future litigation related to PFAS or PFOA, including claims by North Carolina subdivisions not covered by the settlement, personal injury claims, property damage claims, and natural resource damages claims; the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of remaining obligations under the Consent Order; changes in laws and regulations applicable to PFAS chemicals; the performance by each of the parties of their respective obligations under the MOU. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Further lists and descriptions of risks and uncertainties can be found in Chemours’ annual report on Form 10-K for the year ended December 31, 2025 and subsequent reports on Form 10-Q and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Chemours’ consolidated financial condition, results of operations, credit rating or liquidity. Chemours does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
investor@chemours.com
NEWS MEDIA
Jess Loizeaux
Communications Leader, External Affairs
+1.302.685.8554
media@chemours.com